180 Life Sciences Corp. (NASDAQ:ATNF) Sees Significant Increase in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNF) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 119,300 shares, a growth of 107.8% from the March 31st total of 57,400 shares. Currently, 13.0% of the company’s shares are sold short. Based on an average daily trading volume, of 94,000 shares, the short-interest ratio is currently 1.3 days.

180 Life Sciences Stock Performance

Shares of ATNF stock opened at $0.87 on Monday. 180 Life Sciences has a 52 week low of $0.66 and a 52 week high of $17.75. The company’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.85.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC purchased a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences at the end of the most recent reporting period. 4.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 180 Life Sciences in a report on Thursday.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.